Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00028144
DRKS00028144
Not yet recruiting
Phase 2

Personalized Therapy in Rheumatoid Arthritis 2.0 - PETRA 2.0

BKK Landesverband Bayern0 sites440 target enrollmentMarch 1, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsM05M06Seropositive rheumatoid arthritisOther rheumatoid arthritis

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
M05
Sponsor
BKK Landesverband Bayern
Enrollment
440
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 1, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
BKK Landesverband Bayern

Eligibility Criteria

Inclusion Criteria

  • •Adults are eligible to participate,
  • •a. with a confirmed ICD 10 code M05\. and M06\. diagnosis
  • •b. who are insured by the AOK Bayern or a participating BKK
  • •c. who have submitted a declaration of participation in the PETRA 2\.0 model project and
  • •d. a valid data release for innovation fund projects for the PETRA 2\.0 model project.
  • •model project in accordance with § 75 SGB X (approval for the use of
  • •routine data), and
  • •e. who present themselves in a rheumatologists office participating in the study and
  • •f. have sufficient knowledge of German to participate in the survey by means of questionnaires

Exclusion Criteria

  • •Confirmed diagnosis of fibromyalgia (ICD10 M79\.7\)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
BIOmarker-driven DEcision Study with Adalimumab (BIODESA)
ISRCTN61158084niversity Hospital Regensburg (Universitätsklinikum Regensburg) (Germany)60
Active, not recruiting
Phase 3
Comparing the effectiveness of our tailor-made management approach for rheumatoid arthritis with routine care from a clinical, patient, as well as economic point of view
ISRCTN16170070Erasmus University Medical Center300
Recruiting
Phase 4
PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, single-blinded, randomized controlled trial comparing usual care with a tailor-made approachRheumatoid ArthritisSymmetrical (small) joint inflammation with or without auto-antibodies1000381610013361
NL-OMON49359Erasmus MC, Universitair Medisch Centrum Rotterdam300
Not yet recruiting
Phase 1
Management of Rheumatoid Arthritis.Health Condition 1: null- Rheumatoid Arthritis
CTRI/2018/01/011192Central Council for Research in Homoeopathy
Recruiting
Not Applicable
TApering strategies in Rheumatoid Arthritis remission induced by anti-TNF&classic DMARDs. Should we taper the classic DMARD or anti-TNF first?rheumatismrheumatoid arthritis10023213
NL-OMON41388Erasmus MC, Universitair Medisch Centrum Rotterdam355